<i>In Vitro</i>
            Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei

Mounsey, Kate E.; Walton, Shelley F.; Innes, Ashlee; Cash-Deans, Skye; McCarthy, James S.

doi:10.1128/aac.00381-17

Cited by 36 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moxidectin is a newer agent that offers promise; it has better retention in the skin and a much longer half-life (more than 20 days, compared with 14 h for ivermectin) meaning that a single dose may be enough to eliminate infestation [79, 80]. It also appears to prevent reinfestation for a longer period of time after treatment, compared with ivermectin.…”

Section: Treatmentmentioning

confidence: 99%

A Review of Scabies: An Infestation More than Skin Deep

2018

View full text Add to dashboard Cite

Human scabies, a common infestation, has a worldwide distribution with a variable impact and presentation depending on the clinical situation. In developed, high-income settings, health institution and residential home outbreaks challenge health and social care services. In resource-poor settings, it is the downstream sequelae of staphylococcal and streptococcal bacteraemia, induced by scratching, which have a significant impact on the long-term health of communities. Over the past decade scabies has been recognised as a “neglected tropical disease” (NTD) by the World Health Organisation, has an accepted practical system of global diagnostic criteria and is being adopted into integrated programmes of mass drug administration for NTDs in field settings. This review seeks to summarise the recent advances in the understanding of scabies and highlight the advocacy and research headlines with their implication for diagnosis and management of outbreaks and individuals. In addition, it will indicate the priorities and questions that remain.

show abstract

Section: Treatmentmentioning

confidence: 99%

A Review of Scabies: An Infestation More than Skin Deep

2018

View full text Add to dashboard Cite

show abstract

“…40,89 Grade 1: three doses of ivermectin over a period of 1 week. 93,94 It is also less toxic than ivermectin.…”

Section: Other Testsmentioning

confidence: 99%

Scabies: A comprehensive review and current perspectives

Arora

Rudnicka

Sar‐Pomian

et al. 2020

Dermatologic Therapy

114

View full text Add to dashboard Cite

Human scabies is a contagious skin infestation caused by the parasitic mite Sarcoptes scabiei var. hominis. It is a common skin disease worldwide that occurs not only in the underprivileged sections of society but also in developed countries. In 2009, World Health Organization (WHO) recognized scabies as “neglected tropical disease (NTD)” or NTD thus emphasizing the need for community awareness and proper treatment strategies. This review attempts to summarize the varied clinical presentation of the disease and describes the advances in diagnosis and management including the ongoing search for novel agents to overcome the problems associated with conventional treatments. The literature research includes peer‐reviewed articles (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) till February 2020 and reference lists of respective articles. Only articles published in English language were included.

show abstract

“…It has enhanced bioavailability (half-life of over 20 days, compared with 14 h for ivermectin) and better skin retention, meaning that a single-dose regimen may be possible [ 46 ]. Moxidectin is superior to ivermectin against the scabies mite in vitro [ 47 ]; however, clinical studies are required in order to establish suitable doses and evaluate efficacy in cases of scabies.…”

Section: Treatmentmentioning

confidence: 99%

The Skin—A Common Pathway for Integrating Diagnosis and Management of NTDs

Chandler

Fuller

2018

TropicalMed

View full text Add to dashboard Cite

Many of the neglected tropical diseases (NTDs) have major skin manifestations. These skin-related NTDs or ‘skin NTDs’ cause significant morbidity and economic hardship in some of the poorest communities worldwide. We draw attention to the collective burden of skin disease and suggest that the skin be used as a platform for the integration of control activities for NTDs. The opportunities for integration are numerous, ranging from diagnosis and disease mapping to mass drug administration and morbidity management. The dermatology community has an important role to play, and will be expected to support research and control activities globally.

show abstract

In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei

Cited by 36 publications

References 33 publications

A Review of Scabies: An Infestation More than Skin Deep

A Review of Scabies: An Infestation More than Skin Deep

Scabies: A comprehensive review and current perspectives

The Skin—A Common Pathway for Integrating Diagnosis and Management of NTDs

Contact Info

Product

Resources

About